keyword
MENU ▼
Read by QxMD icon Read
search

glatiramer acetate

keyword
https://www.readbyqxmd.com/read/29050818/decreased-serum-levels-of-scd40l-and-il-31-correlate-in-treated-patients-with-relapsing-remitting-multiple-sclerosis
#1
José de J Guerrero-García, Argelia E Rojas-Mayorquín, Yeminia Valle, Jorge R Padilla-Gutiérrez, Víctor A Castañeda-Moreno, Mario A Mireles-Ramírez, José F Muñoz-Valle, Daniel Ortuño-Sahagún
The CD40/CD40L system is a binding key for co-stimulation of immune cells. Soluble form of CD40L has been widely studied as marker of inflammatory and autoimmune diseases. Here we analyze serum concentrations of sCD40L, as well as 14 cytokines, in patients with Multiple Sclerosis (MS) treated with Glatiramer acetate or Interferon beta. In the healthy control group, we found in serum a highly positive correlation between sCD40L and Interleukin (IL)-31, an anti-inflammatory Th2 cytokine. Additionally, an important reduction in IL-31 and sCD40L serum levels, as well as a significant reduction in CD40 mRNA expression and complete depletion of CD40L mRNA, detected from peripheral blood cells, was found in treated patients with MS...
October 5, 2017: Immunobiology
https://www.readbyqxmd.com/read/28940162/infections-in-patients-receiving-multiple-sclerosis-disease-modifying-therapies
#2
REVIEW
Elena Grebenciucova, Amy Pruitt
PURPOSE OF REVIEW: This paper will systemically review the risk of infections associated with current disease-modifying treatments and will discuss pre-treatment testing recommendations, infection monitoring strategies, and patient education. RECENT FINDINGS: Aside from glatiramer acetate and interferon-beta therapies, all other multiple sclerosis treatments to various degrees impair immune surveillance and may predispose patients to the development of both community-acquired and opportunistic infections...
September 22, 2017: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/28935954/process-signatures-in-glatiramer-acetate-synthesis-structural-and-functional-relationships
#3
Víctor R Campos-García, Daniel Herrera-Fernández, Carlos E Espinosa-de la Garza, German González, Luis Vallejo-Castillo, Sandra Avila, Leslie Muñoz-García, Emilio Medina-Rivero, Néstor O Pérez, Isabel Gracia-Mora, Sonia Mayra Pérez-Tapia, Rodolfo Salazar-Ceballos, Lenin Pavón, Luis F Flores-Ortiz
Glatiramer Acetate (GA) is an immunomodulatory medicine approved for the treatment of multiple sclerosis, whose mechanisms of action are yet to be fully elucidated. GA is comprised of a complex mixture of polypeptides with different amino acid sequences and structures. The lack of sensible information about physicochemical characteristics of GA has contributed to its comprehensiveness complexity. Consequently, an unambiguous determination of distinctive attributes that define GA is of highest relevance towards dissecting its identity...
September 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28914229/clinical-effectiveness-and-cost-effectiveness-of-beta-interferon-and-glatiramer-acetate-for-treating-multiple-sclerosis-systematic-review-and-economic-evaluation
#4
G J Melendez-Torres, Peter Auguste, Xavier Armoiry, Hendramoorthy Maheswaran, Rachel Court, Jason Madan, Alan Kan, Stephanie Lin, Carl Counsell, Jacoby Patterson, Jeremy Rodrigues, Olga Ciccarelli, Hannah Fraser, Aileen Clarke
BACKGROUND: At the time of publication of the most recent National Institute for Health and Care Excellence (NICE) guidance [technology appraisal (TA) 32] in 2002 on beta-interferon (IFN-β) and glatiramer acetate (GA) for multiple sclerosis, there was insufficient evidence of their clinical effectiveness and cost-effectiveness. OBJECTIVES: To undertake (1) systematic reviews of the clinical effectiveness and cost-effectiveness of IFN-β and GA in relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) and clinically isolated syndrome (CIS) compared with best supportive care (BSC) and each other, investigating annualised relapse rate (ARR) and time to disability progression confirmed at 3 months and 6 months and (2) cost-effectiveness assessments of disease-modifying therapies (DMTs) for CIS and RRMS compared with BSC and each other...
September 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28860067/a-novel-role-for-osteopontin-in-macrophage-mediated-amyloid-%C3%AE-clearance-in-alzheimer-s-models
#5
Altan Rentsendorj, Julia Sheyn, Dieu-Trang Fuchs, David Daley, Brenda C Salumbides, Hannah E Schubloom, Nadav J Hart, Songlin Li, Eric Y Hayden, David B Teplow, Keith L Black, Yosef Koronyo, Maya Koronyo-Hamaoui
Osteopontin (OPN), a matricellular immunomodulatory cytokine highly expressed by bone marrow (BM)-derived myelomonocytes, regulates immune cell migration, communication, and response to brain injury. Enhanced cerebral recruitment of monocytes and macrophages by immunomodulation using glatiramer acetate (GA) or by peripheral blood enrichment with BM-derived CD115(+) monocytes (Mo(BM)) substantially curbs amyloid β-protein (Aβ) neuropathology and preserves cognitive function in murine models of Alzheimer's disease (ADtg mice)...
August 28, 2017: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/28857632/adherence-persistence-and-discontinuation-among-hispanic-and-african-american-patients-with-multiple-sclerosis-treated-with-fingolimod-or-glatiramer-acetate
#6
Mitzi J Williams, Kristen Johnson, Helen M Trenz, Stephanie Korrer, Rachel Halpern, Yujin Park, Vivian Herrera
OBJECTIVE: Few studies have examined compliance to disease-modifying therapies (DMTs) for multiple sclerosis (MS) in minority populations. This study compared adherence, discontinuation, and persistence for fingolimod (FTY) and glatiramer acetate (GA) initiators among Hispanic and African American patients with MS. METHODS: This retrospective claims data study examined Hispanic and African American adults with MS who initiated FTY or GA between September 1, 2010 and June 30, 2014...
October 3, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28829817/genomic-correlates-of-glatiramer-acetate-adverse-cardiovascular-effects-lead-to-a-novel-locus-mediating-coronary-risk
#7
Ingrid Brænne, Lingyao Zeng, Christina Willenborg, Vinicius Tragante, Thorsten Kessler, Cristen J Willer, Markku Laakso, Lars Wallentin, Paul W Franks, Veikko Salomaa, Abbas Dehghan, Thomas Meitinger, Nilesh J Samani, Folkert W Asselbergs, Jeanette Erdmann, Heribert Schunkert
Glatiramer acetate is used therapeutically in multiple sclerosis but also known for adverse effects including elevated coronary artery disease (CAD) risk. The mechanisms underlying the cardiovascular side effects of the medication are unclear. Here, we made use of the chromosomal variation in the genes that are known to be affected by glatiramer treatment. Focusing on genes and gene products reported by drug-gene interaction database to interact with glatiramer acetate we explored a large meta-analysis on CAD genome-wide association studies aiming firstly, to investigate whether variants in these genes also affect cardiovascular risk and secondly, to identify new CAD risk genes...
2017: PloS One
https://www.readbyqxmd.com/read/28804651/pharmacogenetic-biomarkers-to-predict-treatment-response-in-multiple-sclerosis-current-and-future-perspectives
#8
REVIEW
Patricia K Coyle
Disease-modifying therapies (DMTs) have significantly advanced the treatment of relapsing multiple sclerosis (MS), decreasing the frequency of relapses, disability, and magnetic resonance imaging lesion formation. However, patients' responses to and tolerability of DMTs vary considerably, creating an unmet need for biomarkers to identify likely responders and/or those who may have treatment-limiting adverse reactions. Most studies in MS have focused on the identification of pharmacogenetic markers, using either the candidate-gene approach, which requires prior knowledge of the genetic marker and its role in the target disease, or genome-wide association, which examines multiple genetic variants, typically single nucleotide polymorphisms (SNPs)...
2017: Multiple Sclerosis International
https://www.readbyqxmd.com/read/28770366/management-of-pregnancy-related-issues-in-multiple-sclerosis-patients-the-need-for-an-interdisciplinary-approach
#9
Maria Pia Amato, Antonio Bertolotto, Roberto Brunelli, Paola Cavalla, Benedetta Goretti, Maria Giovanna Marrosu, Francesco Patti, Carlo Pozzilli, Leandro Provinciali, Nicola Rizzo, Nicola Strobelt, Gioacchino Tedeschi, Maria Trojano, Giancarlo Comi
Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease of the central nervous system (CNS), most probably autoimmune in origin, usually occurring in young adults with a female/male prevalence of approximately 3:1. Women with MS in the reproductive age may face challenging issues in reconciling the desire for parenthood with their condition, owing to the possible influence both on the ongoing or planned treatment with the possible consequences on the disease course and on the potential negative effects of treatments on foetal and pregnancy outcomes...
August 2, 2017: Neurological Sciences
https://www.readbyqxmd.com/read/28762192/a-comprehensive-review-on-copemyl-%C3%A2
#10
REVIEW
Pietro Annovazzi, Antonio Bertolotto, Vincenzo Brescia Morra, Claudio Gasperini, Enrico Montanari, Pierluigi Navarra, Francesco Patti, Maria Pia Sormani, Angelo Ghezzi
Economic sustainability is of paramount importance in the rapidly evolving therapeutic scenario of multiple sclerosis (MS). Glatiramoids are a class of drugs whose forefather, glatiramer acetate, has been used as a disease modifying drug (DMD) in patients with MS for over 20 years. Its patent expired in 2015; new versions of such drug are nowadays available on the market, potentially contributing to lowering prices and enhancing a better allocation of economic resources. In this review, we analyze the recommendations underlying the approval of both generic drugs and biosimilars by regulatory authorities, and we provide methodological tools to contextualize the design of studies on these new classes of drugs...
July 31, 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28751099/efficacy-and-safety-of-delayed-release-dimethyl-fumarate-for-relapsing-remitting-multiple-sclerosis-in-prior-interferon-users-an-integrated-analysis-of-define-and-confirm
#11
Óscar Fernández, Gavin Giovannoni, Robert J Fox, Ralf Gold, J Theodore Phillips, James Potts, Macaulay Okwuokenye, Jing L Marantz
PURPOSE: In Phase III studies (DEFINE [Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting MS]/CONFIRM [Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis]), delayed-release dimethyl fumarate (DMF) demonstrated significant efficacy and a favorable benefit-risk profile in patients with relapsing-remitting multiple sclerosis (RRMS). Post hoc analyses of integrated data from DEFINE/CONFIRM were conducted to evaluate the effect of DMF in patients previously treated with interferon (IFN) beta...
July 24, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28721023/persistence-to-disease-modifying-therapies-for-multiple-sclerosis-in-a-canadian-cohort
#12
Dessalegn Y Melesse, Ruth Ann Marrie, James F Blanchard, Bo Nancy Yu, Charity Evans
PURPOSE: To examine the long-term persistence to the first-line injectable disease-modifying therapies (DMTs) for multiple sclerosis (MS) and to identify the factors associated with nonpersistence. PATIENTS AND METHODS: We used population-based administrative data from Manitoba, Canada. All adult subjects who were diagnosed with MS and dispensed a first-line injectable DMT (beta-interferon-1b, beta-interferon-1a, and glatiramer acetate) between 1996 and 2011 and had a minimum of 1 year of follow-up were included...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28706565/once-daily-glatiramer-acetate-decreases-magnetic-resonance-imaging-disease-activity-in-japanese-patients-with-relapsing-remitting-multiple-sclerosis
#13
Takashi Yamamura, Natalia Ashtamker, David Ladkani, Toshiyuki Fukazawa, Hideki Houzen, Masami Tanaka, Toshiro Miura, Volker Knappertz
OBJECTIVE: Multiple sclerosis (MS) prevalence, clinical patterns, and treatment responses vary between races and geographical latitudes. Glatiramer acetate (GA; Copaxone) has provided a safe, effective treatment option for relapsing-remitting MS patients in the USA, European nations, and other countries for decades. The objective of the present study was to assess the safety and efficacy of GA in reducing magnetic resonance imaging disease activity in Japanese patients with active relapsing-remitting MS...
May 2017: Clinical & Experimental Neuroimmunology
https://www.readbyqxmd.com/read/28689102/monthly-methylprednisolone-in-combination-with-interferon-beta-or-glatiramer-acetate-for-relapsing-remitting-multiple-sclerosis-a-multicentre-single-blind-prospective-trial
#14
Serkan Ozakbas, Bilge Piri Cinar, Gorkem Kosehasanoğullari, Turhan Kahraman, Didem Oz, Behice Bircan Kursun
OBJECTIVES: Multiple sclerosis is usually clinically characterized by repeated subacute relapses followed by remissions. Corticosteroids are used for relapses, and this treatment has been shown to increase the speed of recovery from these. We aimed to evaluate the efficacy and safety of pulsed methylprednisolone given every month as an add-on therapy to interferon beta or glatiramer acetate in patients with relapsing-remitting multiple sclerosis. PATIENTS AND METHODS: This was a multi-center, examiner-blinded, prospective study...
September 2017: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/28686222/multiple-sclerosis-immunopathology-and-treatment-update
#15
REVIEW
Narges Dargahi, Maria Katsara, Theodore Tselios, Maria-Eleni Androutsou, Maximilian de Courten, John Matsoukas, Vasso Apostolopoulos
The treatment of multiple sclerosis (MS) has changed over the last 20 years. All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical challenge in MS to develop a treatment for progressive forms. The most common injectable disease-modifying therapies in RRMS include β-interferons 1a or 1b and glatiramer acetate. However, one of the major challenges of injectable disease-modifying therapies has been poor treatment adherence with approximately 50% of patients discontinuing the therapy within the first year...
July 7, 2017: Brain Sciences
https://www.readbyqxmd.com/read/28680308/clinical-radiological-and-electrophysiological-comparison-of-immunomodulatory-therapies-in-multiple-sclerosis
#16
Gençer Genç, Şeref Demirkaya, Semai Bek, Zeki Odabaşi
INTRODUCTION: Although it has been shown that immunomodulatory therapies (IMTs) in multiple sclerosis (MS) can modify the course of the disease by reducing the relapse rate and delaying the progression of disability, no study comparing IMTs head-to-head in terms of clinical, radiological, and electrophysiological changes is available. We aimed to investigate the effects of interferon-beta (IFN-B) 1b, IFN-B-1a subcutaneous (sc), IFN-B-1a intramuscular (im), and glatiramer acetate (GA) therapies on clinical, electrophysiological, and radiological findings...
June 2017: Noro Psikiyatri Arsivi
https://www.readbyqxmd.com/read/28649912/comparative-effectiveness-of-rituximab-relative-to-ifn-%C3%AE-or-glatiramer-acetate-in-relapsing-remitting-ms-from-the-swedish-ms-registry
#17
Tim Spelman, Thomas Frisell, Fredrik Piehl, Jan Hillert
OBJECTIVE: To compare treatment effectiveness and persistence in relapsing-remitting multiple sclerosis patients who initiated rituximab versus glatiramer acetate (GA) or interferon-beta (IFN-β). METHODS: A total of 461 patients from the Swedish MS registry in the rituximab arm were propensity score matched on a 1:2 basis with 922 patients from the IFN-β/GA comparator, between April 2005 and November 2015. Annualised relapse rate (ARR) was compared using the Poisson method...
June 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28642148/biological-activity-of-glatiramer-acetate-on-treg-and-anti-inflammatory-monocytes-persists-for-more-than-10years-in-responder-multiple-sclerosis-patients
#18
Michela Spadaro, Francesca Montarolo, Simona Perga, Serena Martire, Federica Brescia, Simona Malucchi, Antonio Bertolotto
Glatiramer acetate (GA) is a widely used treatment for multiple sclerosis (MS), with incompletely defined mechanism of action. Short-term studies suggested its involvement in the modulation of anti-inflammatory cytokines and regulatory T cells (Treg), while long-term effect is still unknown. To investigate this aspect, we analyzed by flow-cytometry peripheral-blood Treg, natural killer (NK), CD4 and CD8 T-cells and anti-inflammatory CD14(+)CD163(+) monocytes from 37 healthy donor and 90 RRMS patients divided in untreated, treated with GA for 12months and from 34 to 192months...
August 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28617366/-an-effect-of-disease-modifying-drugs-on-the-development-of-children-born-to-mothers-with-multiple-sclerosis
#19
D S Kasatkin, N N Spirin, T V Vinogradova, A S Shytova
AIM: To evaluate an effect of mother's treatment with disease-modifying drugs (DMD) on the mental and physical development of the child in the first year of life. MATERIAL AND METHODS: Thirty pregnancies resulted in birth of live babies in patients with multiple sclerosis (MS) were studied. The diagnosis of MS was made to the mother before conception of the child. Seven mothers did not receive DMD at the moment of conception (controls), 13 mother were treated with interferon-beta (IFN) and 10 with glatiramer acetate...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28607752/enhanced-disease-reduction-using-clozapine-an-atypical-antipsychotic-agent-and-glatiramer-acetate-combination-therapy-in-experimental-autoimmune-encephalomyelitis
#20
Laura K Green, Pirooz Zareie, Nikki Templeton, Robert A Keyzers, Bronwen Connor, Anne Camille La Flamme
BACKGROUND: Atypical antipsychotic agents (AAP) alleviate the symptoms of severe mental health disorders, such as schizophrenia, by antagonizing dopamine and serotonin receptors. Recently, AAP have also been shown to exhibit immunomodulatory properties in the central nervous system (CNS). OBJECTIVE: Building on research which demonstrated the ability of the AAP risperidone and clozapine to modify the disease course of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), we aimed to more fully investigate the potential of clozapine as a possible treatment for MS...
January 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
keyword
keyword
80154
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"